(Adnkronos) - - RSVI-301, a new drug candidate adopting miRNA technology, enters the technology export process.
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced that it has signed a Material Transfer Agreement (MTA) with one of the largest global